Tech Transfer Roundup: Sanofi Gets IP For Multiple Myeloma From Memorial Sloan Kettering

Sanofi signed an agreement on 6 July to acquire intellectual property covering non-chimeric antigen receptor (CAR) use of a novel binding domain that targets GPRC5D (G Protein-Coupled Receptor Family C Group 5 Member D) from Eureka Therapeutics, Inc. and Memorial Sloan Kettering Cancer Center. Eureka and the center each gets an undisclosed upfront payment and can split up to $1bn development, regulatory and sales milestones plus potential sales royalties from Sanofi.

GPRC5D is seen as a target that might offer a promising pathway for treating MM, especially in relapsed patients, Sanofi said. The French pharma currently has no multiple myeloma candidates in clinical development, according to Biomedtracker. It obtained US approval of the anti-CD38 antibody Sarclisa (isatuximab) for MM in March 2020, with EU approval occurring a few weeks later